利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.012 秒)

    COMPOSITION CONTAINING STYRAXLIGNOLIDE A OR THE AGLYCONE THEREOF AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING ASTHMA
    2.
    发明公开
    COMPOSITION CONTAINING STYRAXLIGNOLIDE A OR THE AGLYCONE THEREOF AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING ASTHMA 有权
    乐曲或STYRAXLIGNOLID苷元作为活性预防和治疗哮喘

    公开(公告)号：EP2641604A2

    公开(公告)日：2013-09-25

    申请号：EP11842263.3

    申请日：2011-11-17

    申请人： Korea Research Institute of Bioscience and Biotechnology

    发明人： AHN, Kyung Seop ,  JANG, Ha Young ,  OH, Sei Ryang ,  LEE, Hyeong Kyu ,  KWON, Ok-Kyoung ,  KIM, Semi ,  KIM, Jung Hee ,  KIM, Doo-Young

    IPC分类号： A61K31/706 ,  A61K31/7048 ,  A61K31/7042 ,  A61P11/06

    CPC分类号： A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/343 ,  A61K36/185 ,  A23V2200/314 ,  A23V2250/21 ,  A23V2250/2116

    摘要： The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of Styrax japonica, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.

    摘要翻译： 本发明涉及一种药物组合物，用于预防或治疗哮喘，含styraxlignolide A中的组合物或它们的糖苷配基为活性成分。 更具体地，styraxlignolide的化合物是一个分离从茎和苏合香粳稻的树皮，和styraxlignolide A或homoegonol，所有这是styraxlignolide A和哪个的糖苷配基具有改善的安全性，具有衰减体重减轻及气道高反应性的效果，抑制性的代 在气道反应性氧物质，抑制性产生的IgE，TGF-²1，和IL-17的血清和支气管肺泡灌洗液中的，抑制性支气管内炎症细胞浸润，和抑制一个粘液栓和皮下纤维化的形成在哮喘诱发的 小鼠模型。 因此，styraxlignolide或homoegonol可以被有效地用作用于预防或治疗在气道重塑支气管哮喘哪个已经进展的药物组合物的活性成分。